PP
NGEN

Paladin Partners’s NervGen Pharma NGEN Stock Holding History

Paladin Partners’s Portfolio NGEN Stock Details NGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.6K Hold
10,000
– – 0.01% 109
2026
Q1 		$37.7K Hold
10,000
– – 0.03% 78
2025
Q4 		$56K Buy
+10,000
New +$56K 0.04% 62

Other funds holding NGEN

EAM
Empery Asset Management New York $86.5M AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $5.1B AUM 39.13% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Paladin Partners's NGEN Position: Q2 2026 in Review

Paladin Partners held its NervGen Pharma (NGEN) position steady in Q2 2026 at 10,000 shares worth $20.6K. The position accounts for 0.01% of the portfolio, ranked #109.

Paladin Partners first reported a position in NGEN in Q4 2025 and has held it in 3 quarters since. The position peaked at $56K in Q4 2025. 62 funds tracked by Wall St. Rank hold NGEN as of Q2 2026.

  • Paladin Partners held 10,000 shares of NervGen Pharma worth $20.6K as of Q2 2026.
  • Paladin Partners left its NervGen Pharma share count unchanged in Q2 2026.
  • NervGen Pharma made up 0.01% of Paladin Partners's portfolio in Q2 2026, its #109 holding.
  • Paladin Partners first reported a position in NervGen Pharma in Q4 2025 and has held it in 3 quarters since.
  • Paladin Partners's NervGen Pharma position peaked at $56K in Q4 2025.
  • 62 funds tracked by Wall St. Rank held NervGen Pharma as of Q2 2026.

Based on Paladin Partners's 13F filing for Q2 2026, filed 7 Aug 2026.